← Leaderboards
Shu Wang
Texas Tech University
$1,057,200
Attributed
$1,405,198
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $696K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,405,198 · 3
By mechanism
R15$709,201 · 2
R01$695,997 · 1
Top collaborators
- Wuqiang Zhu1 shared
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoToxic EffectUnited StatesInsightCellsImmunohistochemistryHealth SciencesInflammationDiagnosisBloodEncapsulatedFeedingHeartImmunogenicityDisorder PreventionBiocompatibleAffinityBiologicalAdverse EffectsBlood CirculationCharacteristicsChronic DiseaseDrug Delivery SystemsAorta
Grant awards (3)
Programmed Cell Death 4 in Doxorubicin-Induced Cardiotoxicity$695,997
R01 · FY2025 · HL
Anti-obesity effects of adipose-targeting resveratrol nanocarriers$395,239
R15 · FY2015 · AT · contact PI
Green Tea Nanocarriers: A Promising Approach for the Prevention and Treatment of$313,962
R15 · FY2011 · AT · contact PI